Skip to main content
Toggle navigation
Login
Search
Home
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
L
Lachi Silva, Larissa
Novartis
(
S-089
)
Use of population time-activity curve modeling and simulation to support the reduced tumor dosimetry collection timepoints in radioligand therapy (RLT) clinical trials
Larissa Lachi Silva
Favorite
Langevin, Brooke
Center for Translational Medicine, University of Maryland Baltimore
(
S-100
)
Understanding How Low Calorie Sweeteners Pass from Mother to Infants Through Breastmilk – Insights from Population Pharmacokinetic Modeling
Brooke Langevin
Favorite
Lee, Dongjin
Amgen
(
S-023
)
Deep Learning-Based Autoencoder for Outlier Detection in Dosing and Concentration-Time Data: Enabling Reliable Population Pharmacokinetic Modeling
Dongjin Lee
Favorite
Lee, Grace
Critical Path Institute
(
S-016
)
Verification of an algorithm for detection of pronation-supination movements in Parkinson’s disease.
Grace Lee
Favorite
Lennie, Janelle
GSK
(
M-045
)
Ghqc: An R-based Open-Source Tool for Semi-Automated Quality Control on GitHub
Janelle Lennie
Favorite
Leonov, Vladislav
InSysBio UK Ltd
(
M-068
)
Optimizing QSP Modeling Workflows with CYTOCON DB: A Comprehensive Repository of In Vivo Cell and Cytokine Concentrations
Vladislav Leonov
Favorite
(
S-074
)
From Data to Parameters: FIVEDB as a Tool for Efficient QSP Model Calibration
Vladislav Leonov
Favorite
Liang, Min
Moderna
(
S-104
)
Model-Informed Dose Selection for mRNA-3927 in Participants with Propionic Acidemia (PA)
Min Liang
Favorite
Liao, Xiaozhi
UNC-Chapel Hill
(
T-092
)
Mechanistic Modeling of Bispecific Antibody Combination Therapy to Optimize TumorKilling in Cancer Immunotherapy
Xiaozhi Liao
Favorite
Li, ChongHua
(
T-094
)
Population Pharmacokinetics of Brensocatib in Adult and Adolescent Patients with Non-Cystic Fibrosis Bronchiectasis (BE)
ChongHua Li
Favorite
Lim, Jiwoo
College of Pharmacy, Yonsei University
(
S-079
)
Osimertinib optimal dosing through population pharmacokinetics in virtual patients with NSCLC
Jiwoo Lim
Favorite
Lin, Chih-Wei
Amgen
(
S-026
)
Evaluation of Fluctuating Drug Concentration and Pharmacokinetic Effects on Time-to-event Endpoint Using Proportional Hazard Cox Regression in NONMEM
Chih-Wei Lin
Favorite
Lindauer, Andreas
Calvagone SAS
(
M-075
)
From hot to cold: Modeling radiocopper kinetics in Wilson’s Disease to simulate cold copper endpoints
Andreas Lindauer
Favorite
Lingineni, Karthik
Novartis Pharmaceutical Corporation
(
M-106
)
An Integrated model of Lu-PSMA-617 dose, tumor dosimetry, PSA and OS to enable future study design
Karthik Lingineni
Favorite
Lin, Jiaye
Pfizer Ltd.
(
T-002
)
Concentration-QTc modeling for ponsegromab using pooled data from 3 phase 1 studies in healthy participants
Jiaye Lin
Favorite
Linsmeier, Ian
Arcus Biosciences, Inc.
(
T-044
)
GitHub-based QC Review Workflow for Pharmacometrics Projects
Ian Linsmeier
Favorite
Lint, Annabelle
University of Pittsburgh
(
M-084
)
Modeling Blood Urea Nitrogen (urea) Dynamics to Estimate Dialysis Adequacy
Annabelle Lint
Favorite
Li, Peizhi
University of Iowa College of Pharmacy
(
M-038
)
Evaluation of Azithromycin Disposition in Pregnant Women Undergoing Cesarean Delivery – A Population-Based PBPK Modeling Approach
Peizhi Li
Favorite
Liu, Catherine
UCSD
(
M-009
)
Translation of a Preclinical Tumor Growth Inhibition Model to a Clinical Setting: Two Approaches to Incorporate Resistance in a Tumor Dynamics Model
Catherine Liu
Favorite
(
M-010
)
Population Pharmacokinetic Modeling of Encorafenib and LHY746 In Participants with Solid Tumors in Phase 2 Studies: A Sequential Parent-Metabolite Model
Catherine Liu
Favorite
Liu, Xiaoxi
CSL Behring
(
T-061
)
A semi-mechanistic PKPD model of CSL112 harmonizes the differential cholesterol efflux capacities (CEC) of high-density lipoprotein across different dose groups
Xiaoxi Liu
Favorite
Li, Xinnong
University at Buffalo
(
T-019
)
Application of NSGA-II and pyDarwin in Multi-objective Optimization for Population Pharmacokinetic (PopPK) Model Selection
Xinnong Li
Favorite
Liyanage, Marlon
Pfizer Inc
(
S-076
)
Exposure-Response Characterization of the Safety Profile for a Novel KAT6 Inhibitor, PF-07248144, For Use In Dose Optimization During a Phase 1 First-in-Patient Study
Marlon Liyanage
Favorite
Li, Yannuo
(
M-057
)
Quantitative Systems Pharmacology Modeling to Support First-in-Human Dose Selection for a CD3 Bispecific Antibody in B-Cell Lymphoma and Renal Cell Carcinoma
Yannuo Li
Favorite
Li, Yingyi
Johnson and Johnson Innovative Medicine
(
M-096
)
Simultaneous PASI Exposure Response Analysis of Ustekinumab in Subjects with Psoriasis and Psoriatic Arthritis
Yingyi Li
Favorite
Li, Yisheng
University of Texas MD Anderson Cancer Center
(
T-041
)
An extended Bayesian semi-mechanistic dose-finding design in oncology using pharmacokinetic and pharmacodynamic information
Yisheng Li
Favorite
Li, zhenhong
Nimbus Therapeutics
(
S-019
)
Applying Mechanistic PKPD Models to Differentiate Inhibitors of Werner Syndrome Helicase Based on Predicted in vivo Target Engagement
zhenhong Li
Favorite
Lohmer, Lauren
Indivior, Inc
(
M-073
)
Exposure-Response Analyses for Monthly Buprenorphine Extended-Release (BUP-XR) in Patients with Opioid Use Disorder and Frequent Fentanyl Use
Lauren Lohmer
Favorite
Long, Yuhan
University of Minnesota
(
M-097
)
Accounting for Temporal Differences in Fetal Exposure during Pregnancy using Masking
Yuhan Long
Favorite
Luanpaisanon, Alice
University of Virginia
(
T-034
)
In silico model of hypertrophic cardiomyopathy caused by MYBPC3 mutation predicted key drivers of cardiomyocyte morphology
Alice Luanpaisanon
Favorite
Lu, Dan
Genentech
(
M-092
)
QSP modeling to inform key clinical dosing regimen decisions for an engineered IL15 cytokine Efbalropendekin alfa in patients with solid tumors
Dan Lu
Favorite
Lumen, Annie
Clinical Pharmacology Modeling & Simulation, Amgen
(
T-028
)
A Mechanistic Pharmacokinetics and Pharmacodynamics (PK/PD) Platform Model for Induced proximity-based therapeutics - PROTACs
Annie Lumen
Favorite
Luo, Dandan
Johnson & Johnson
(
M-020
)
Assessment of Drug-Drug Interaction Effect of Gastric Acid Reducing Agents on Lazertinib Exposure in EGFR-Mutated Non-Small Cell Lung Cancer
Dandan Luo
Favorite
